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Abstract
Background
The grades of recommendation, assessment, development and evaluation (GRADE) ap-
proach is widely implemented in systematic reviews, health technology assessment and
guideline development organisations throughout the world. A key advantage to this ap-
proach is that it aids transparency regarding judgments on the quality of evidence. However,
the intricacies of making judgments about research methodology and evidence make the
GRADE system complex and challenging to apply without training.
Methods
We have developed a semi-automated quality assessment tool (SAQAT) l based on
GRADE. This is informed by responses by reviewers to checklist questions regarding char-
acteristics that may lead to unreliability. These responses are then entered into the Bayes-
ian network to ascertain the probabilities of risk of bias, inconsistency, indirectness,
imprecision and publication bias conditional on review characteristics. The model then com-
bines these probabilities to provide a probability for each of the GRADE overall quality cate-
gories. We tested the model using a range of plausible scenarios that guideline developers
or review authors could encounter.
Results
Overall, the model reproduced GRADE judgements for a range of scenarios. Potential ad-
vantages over standard assessment are use of explicit and consistent weightings for differ-
ent review characteristics, forcing consideration of important but sometimes neglected
characteristics and principled downgrading where small but important probabilities of down-
grading are accrued across domains.
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Conclusions
Bayesian networks have considerable potential for use as tools to assess the validity of re-
search evidence. The key strength of such networks lies in the provision of a statistically co-
herent method for combining probabilities across a complex framework based on both
belief and evidence. In addition to providing tools for less experienced users to implement
reliability assessment, the potential for sensitivity analyses and automation may be benefi-
cial for application and the methodological development of reliability tools.
Introduction
The fundamental objective of evidence-based health care is to enable clinicians or policy mak-
ers to make informed decisions regarding the development or delivery of effective health inter-
ventions. The reliability of the evidence underpinning decisions is important particularly
where high and low quality evidence result in different conclusions regarding effectiveness. Re-
searchers have developed a range of tools for considering the validity of conclusions from re-
search synthesis. Easily applicable tools [e.g. 1] focus on the process and robustness of research
synthesis but their practical utility is limited as they do not provide direct information on the
quality of evidence underpinning decisions. This requires evaluation of biases across studies, as
well as biases detected during the process of evidence synthesis.
The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) ap-
proach [2–16] is the most widespread method for rating the quality of evidence in healthcare.
GRADE has been adopted by organisations such as the World Health Organization, Cochrane
Collaboration, Agency for Healthcare Research and Quality, and National Institute for Health
and Clinical Excellence.
The GRADE approach is described in online support for software [http://ims.cochrane.org/
revman/gradepro] and in a BMJ series of papers in 2008, with updated guidance available in a
Journal of Clinical Epidemiology series beginning in 2011 [2–16]. According to the GRADE ap-
proach, evidence based on randomised controlled trials is considered high quality (reliable),
but can be downgraded across five domains: risk of bias, inconsistency, indirectness, impreci-
sion, publication bias. Non-randomised studies begin at low quality evidence but their rating
can be upgraded (provided no other limitations have been identified in the five domains) for
three primary reasons: large magnitude of effect, evidence of a dose-response effect, all plausi-
ble confounding taken into account. This then leads to a rating on the quality of evidence for
each outcome of high, moderate, low or very low where high indicates that any future research
is likely to be confirmatory.
A key advantage of GRADE is that it leads to transparent judgments on the quality of evi-
dence. Proposing key specific factors that may lead to downgrading the quality of evidence
(and the need to state reasons for each downgrade) provides a clear rationale for such judge-
ments. Another desirable feature of the approach is the ability to make complex, nuanced
judgements using a common framework that is not based solely on review process or the type
of evidence included in the synthesis [17].
GRADE is not without detractors [18]. Specific criticisms include failure to adequately ac-
count for dependencies across domains, and lack of nuanced judgements when combining
multiple sources of bias to produce an overall judgement on the strength of evidence. These
criticisms partly reflect limitations in current knowledge. Many aspects of GRADE are
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consensus based due to limitations in the current evidence base and the approach continues to
be modified and updated in the light of new evidence from methods research.
The widespread acceptance of evidence-based health care means that systematic reviews are
widely viewed as gold standard evidence. Uncertainty associated with reviews of poor quality
studies, with poorly framed questions or employing poor methodology is often underesti-
mated. Rating the strength of a body of evidence is a key factor in translating to clinicians and
decision-makers the confidence with which they should interpret these results [19]. Although
we acknowledge such judgements will always require a certain level of subjectivity, reviewers
should be expected to meet a reasonable level of consensus particularly in the context of evi-
dence based decision making which is founded on the principles of transparency and scientific
rigour. In this paper we propose a quality assessment tool using Bayesian networks to formalise
the structure provided by the GRADE framework, and explicitly weighting the different items
that combine to reduce overall strength of evidence. This will facilitate transparent and consis-
tent application of GRADE and communicate uncertainty in the assessment which is currently
lacking. Such networks still require value judgements in parameterisation and will likely pro-
vide less nuanced judgements than those made by experienced methodologists, but may in-
crease the repeatability of assessment making widespread application by non-specialists
feasible. They could also lead to the automation or semi-automation of quality assessments.
Bayesian networks evolved in the early 1990s based on the seminal works of researchers
such as Pearl, Lauritzen, Dawid and Spiegelhalter. Bayesian networks (sometimes referred to as
causal diagrams, directed acyclic graphs or DAGs) are statistical models of a domain, compris-
ing a network of nodes connected by directed links, with a probability function attached to
each node [20]. They are often used to model uncertainty, and therefore provide a tool for deci-
sion-making under uncertainty [20]. This uncertainty can arise owing to an imperfect under-
standing of the domain, incomplete knowledge of the state of the domain, randomness in the
mechanisms governing the behaviour of the domain, or any combination of these [21,22]. Pre-
viously proposed tools have assessed quality in control processes [23,24]. Here we suggest a
tool based on Bayesian networks can bring the advantages of transparency, reliability and sta-
tistical coherence to the assessment of reliability of evidence from research syntheses.
Development of the Bayesian Network
We reviewed the updated guidance in the Journal of Clinical Epidemiology [2, 16] on down-
grading evidence from meta-analysis based on randomised controlled trials, and deconstructed
the information underlying the five domains. Two authors [GS, NM] developed a checklist of
questions underpinning the GRADE approach based on the JCE series of articles with differ-
ences in interpretation resolved through discussion (supplementary material checklist and [17]
for further details).
The same two authors built a casual diagram explicitly mapping the relationships between
questions and domains (Fig. 1). For example, we ask a question about allocation concealment
and a question about random sequence generation to ascertain the probability of selection bias
(S1 Table). The structure of the causal diagram was checked for consistency with empirical evi-
dence and the GRADE approach by two other authors [JPTH, HS] with any differences in in-
terpretation resolved through discussion. Two authors [GS, NM] then attributed probabilities
to each domain, conditional on the answers to the questions informing it. For example, if there
was no allocation concealment and inadequate random sequence generation then the probabil-
ity of selection bias being realised (high) was judged to be 1.0 (S1 Table). These probabilities
were elicited through discussions between the two authors and reading the GRADE literature.
Any differences in proposed probabilities were resolved through discussion or consultation
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with a third author [JPTH]. We recognise that all the probabilities throughout the paper are
(reasonably arbitrary) proposals reflecting either logic or empirical evidence and expert con-
sensus regarding threats to validity of research synthesis. They can easily be amended to reflect
alternative judgements or evidence [25]. The rationale for the assignment of probabilities for
each domain is outlined below.
Reviewers wanting to use the tool to obtain a judgement on the strength of evidence answer
the checklist questions (for the full checklist of question please see supplementary materials, or
for further details see [17]). These responses to the checklist questions are entered into the
Bayesian network which then estimates the probability of there being no limitation, serious
limitations, very serious limitations (i.e. no downgrade, downgrade one level, downgrade two
levels for the GRADE assessment). The final judgement of strength of evidence is then estimat-
ed by the Bayesian network based on the estimates of bias/limitations in each of the five do-
mains (i.e. risk of bias, imprecision, indirectness, inconsistency, publication bias).
Risk of bias
For the risk of bias associated with randomised trials we referred to guidance from the
Cochrane Collaboration [26] in addition to the GRADE literature. Selection bias was based
on allocation concealment and random sequence generation, which were given equal weight
(S1 Table). Performance bias was determined solely by blinding (S2 Table). Detection bias was
based on blinding and whether the outcome was objective, being most likely when a subjective
outcome was measured unblinded (S3 Table). The severity of attrition bias depends on the
event rate in relation to losses to follow up with low ratios being problematic. We used an arbi-
trary value for loss to follow up of 20% as a surrogate measure (S4 Table). Reporting bias was
Fig 1. A logic map depicting the GRADE framework for assessing strength of evidence. (This formulation considers risk of bias only for randomised
control trial study designs).
doi:10.1371/journal.pone.0114497.g001
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related to outcome reporting (S5 Table). An additional “catch all” item was used to capture
other biases (e.g. baseline imbalance) and early stopping (S6 Table). This framework represents
a highly simplified variant of the more nuanced guidance provided by the Cochrane Collabora-
tion [26]. We used a simple decision rule to derive the conditional probabilities underlying risk
of bias. Selection bias results in serious limitations, or very serious limitations if combined with
a problem from any alternative source; two problems from other sources (e.g. detection bias,
attrition bias) result in serious limitations, whilst three problems result in very serious limita-
tions (S7 Table). The option of answering questions as unclear results in no downgrading (the
probabilities are equivalent to the “low” state) but their inclusion allows users to distinguish
judgements regarding absence of bias from judgements regarding absence of evidence of bias.
Where unclear judgements are intermediate between alternative options, an alternative para-
metisation may be appropriate if a more conservative approach to assessing poorly reported re-
views is desired.
Inconsistency
Inconsistency is the extent to which individual study effects differ. The determinants of incon-
sistency are substantial variation in effects across studies (in both magnitude and direction),
and sufficient information within studies to ascertain that differences are not due to chance.
Consistency is assessed using a statistical measure of the proportion of detectable between
study variation that is not due to chance (I2) whilst the degree of overlap of study confidence
intervals provides a heuristic interpretation. In our schema the latter carries more weight than
the former with probabilities for “some overlap” intermediate between the values assigned to
“substantial overlap” and “no overlap” (S8 Table). The extent of evidence for heterogeneity can
be measured in terms of the statistical significance of the heterogeneity test (S9 Table). An un-
clear judgement here is intermediate, in contrast to the risk of bias domain. ‘Study distribution’
considers whether there is meaningful variation in study effects and variation in effect direc-
tion. Inconsistency is more likely to be substantial when there is variation in both, whilst varia-
tion in direction is unimportant if there is not judged to be meaningful variation in effects
(S10 Table). Overall inconsistency is serious to very serious if study distributions are wide, with
consistency and amount of information carrying less weight (S11 Table).
Indirectness
Assessing the applicability or indirectness of evidence involves many difficult value judgements
regarding the match between the available evidence and the decision setting (which may itself
vary) or research question. The GRADE literature suggests assessing how directly the body of
evidence relates to the question asked, in terms of population, intervention, comparator, and
outcome scale or outcome time frame. In that framework the use of surrogate outcomes is a
major cause of indirectness (S12 Table). Another determinant of indirectness is the nature of
the comparison, with direct comparison of active interventions generally considered more ro-
bust than indirect comparisons via a common comparator (S13 Table). Overall indirectness is
likely very serious when surrogate outcomes and other indirectness, such as lack of population
directness are combined, with either alone likely to be serious (S13 Table).
Imprecision
Imprecision refers to uncertainty in the magnitude of the point estimate, typically expressed
using 95% confidence intervals. Where the confidence interval is consistent with both benefit
and harm, imprecision is high. In the context of guideline development, if alternative manage-
ment decisions would be made based on utilising the effects compatible with those reflected in
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the CI, then the consequences of imprecision are more serious, warranting further downgrad-
ing. Whether confidence intervals are consistent with benefit and harms depends partly on the
effectiveness of the intervention and partly on the amount of statistical information, which in
turn depends on choice of meta-analytical model, study size, number of studies, event rates
and heterogeneity. Given the complexity of the relationships between these components, we
chose to consider statistical information as a function of the size of studies, number of studies
and event rate (for dichotomous outcomes) (S14 Table). Overall imprecision was likely to be
very high where statistical information was low and the summary effect was consistent with
benefit and harms (as defined using a minimally important difference) (S15 Table).
Publication bias
Publication bias is determined by a combination of discrepancy between published and unpub-
lished studies, amount of statistical information, industry influence and search integrity with the
former carrying greatest weight (S16 Table). Search integrity is determined by the comprehen-
siveness of the search, inclusion of grey literature and the application of any language restrictions
(Fig. 1). The discrepancy between studies is informed by funnel plot asymmetry in addition to
subjective assessment (Fig. 1). In contrast to the other domains where bias is classified as no bias,
serious bias or very serious bias, publication bias is either not detected or strongly suspected re-
flecting the inherent uncertainty of identifying this type of bias (S15 Table).
Combining information across domains
GRADE generally uses a considered judgement across domains to determine overall quality
of evidence, with serious limitations in any domain resulting in a downgrade of one category
(e.g. high to moderate). We used conditional probabilities of zero or one to implement the
GRADE framework determining overall quality of evidence [http://ims.cochrane.org/revman/
gradepro]. Two serious limitations or a very serious limitation within one domain result in a
downgrade of two categories (e.g. high to low), whilst three serious limitations or one serious
and one very serious limitations always results in a very low quality rating of evidence.
Application of the tool
We considered five scenarios to illustrate the performance of the tool when rating the quality
of systematic review evidence.
Scenario one: We considered a hypothetical “high quality” review of fifteen large rando-
mised controlled trials where the blinding of participants was unclear and there was some het-
erogeneity but no other problems were encountered.
Scenario two: This is identical to scenario one, but the review evidence comes from three
small randomised controlled trials.
Scenario three: This is identical to scenario one, but additional problems are identified with
use of a surrogate outcome and inadequate randomisation methods
Scenario four: We considered a meta-analysis of seven moderate sized studies where report-
ing risk of bias was unclear, heterogeneity was high, effect direction was inconsistent and all as-
pects of the search for evidence were poor.
Scenario five: We considered a meta-analysis of five small studies, with unclear reporting of
risk of bias, substantial variation in effect magnitude and direction but substantial overlap of
individual study confidence intervals, high heterogeneity, surrogate outcome and industry
funding.
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We also randomly selected four Cochrane systematic reviews [27–30] with GRADE assess-
ments and compared overall assessments of quality presented in summary of findings tables
with the results from the Bayesian network to provide an initial proof of principle.
The five scenarios illustrate strong congruence between the judgements derived from the
tool and a GRADE assessment based on guidance from the GRADE literature (S17 Table). Re-
liable evidence from a robust meta-analysis of large randomised controlled trials has a 90%
probability of high quality evidence with some uncertainty accruing from the presence of het-
erogeneity. Because only performance bias is realised, there is no downgrading for risk of bias
(S17 Table).
In the same situation but with a few small trials (scenario two), the evidence becomes mod-
erate to high as a result of imprecision (72% serious) and publication bias (28% suspected) ac-
counting for the uncertainty inherent in meta-analyses of a few small studies.
For scenario three, the addition of known limitations (inadequate randomisation and surro-
gate outcomes) to the first scenario results in more severe downgrading (moderate to low over-
all) as a result of additional risk of bias (50% serious) and indirectness (70% serious to very
serious).
Scenario four illustrates the accrual of probabilities across domains, where the probability of
downgrading within a domain remains less than 50%. Thus the combination of potential prob-
lems is reflected in a high to moderate classification.
The final scenario represents low quality evidence where problems are more likely than not,
across multiple domains, resulting in a 65% probability of very low evidence.
Agreement on overall reliability between the Bayesian network and the summary of findings
in four reviews [27–30] assessing 13 outcomes was substantial (kappa 0.69; 95% confidence in-
terval 0.38 to 0.99). There was one substantial discrepancy, where the original review did not
downgrade evidence on the basis of imprecision despite the confidence intervals of the point
estimate being consistent with benefit and harms. Minor discrepancies also occurred, most
commonly in assessment of risk of bias, where standard assessment resulting in downgrading
for the identification of a single problem (one instance) or where risk of bias was unclear (three
instances). Reasons for these differences may relate to differing expertise or value judgements
underlying GRADE assessment or judgments relating to the severity and relative weightings of
domains. We emphasise that these are preliminary results intended as proof of principle. Addi-
tional work to validate the model more formally is presented in further work.
Discussion
The GRADE framework provides a mechanism by which systematic review evidence can be in-
terpreted in terms of quality of evidence to inform the development of guidelines or evidence
briefings [2–16]. Despite providing a consistent framework for making transparent judge-
ments, GRADE does not have high repeatability [3, 19]. The complexity of the approach, whilst
necessary to allow nuanced judgements, also results in potential for misapplication, particularly
with inexperienced reviewers or those lacking GRADE training. One approach to dealing with
this is to ensure that all raters have sufficient experience and training. However, another ap-
proach is to see if statistical approaches can support novices based on the experience of others,
including experienced raters. Users still require training to make consistent value judgements
to parametise the model, but judgments regarding impact on overall validity are automated.
Formal testing of consistency of application and congruence with existing mechanisms re-
quires further exploration, but our initial results suggest that a quality assessment tool based on
a probabilistic Bayesian network may prove a useful tool for GRADE implementation. We con-
sider the potential advantages and limitations of probabilistic assessment below.
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Potential advantages of the tool
The primary advantages of the tool are that it requires users to consider all items and to consid-
er them consistently. For example, sample size and number of studies have a bearing on our
ability to detect both overall effects and specific biases, but the impacts are indirect and there-
fore not always considered. Thus a standard GRADE assessment applied by an inexperienced
researcher may or may not distinguish between the results of robust, consistent meta-analyses
based on large number of large studies or few small studies. Explicit inclusion of size and num-
ber of studies in the Bayesian network ensures appropriate circumspection in the latter circum-
stance, given that around a quarter of evidence from meta-analysis of few small trials is
considered reliable [34].
Even where GRADE users consider all items, they may not coherently combine the informa-
tion when making judgements. For example, high heterogeneity may be interpreted as incon-
sistency even when there is no variation in effect direction and the lower 95% confidence
intervals of studies are consistent with a minimally important difference. The use of condition-
al probabilities ensures that these relationships are consistently and explicitly considered. This
may be especially important when intermediate states are encountered. For example, it may be
relatively easy to make a repeatable decision regarding imprecision when point estimates are
consistent with benefits and harms, study numbers are low and sample sizes are small but if
these items are intermediate, it is difficult to operationalize a consistent decision. The use of
conditional probability tables mean that intermediate values can be calibrated with reference to
worst and best case scenarios and applied consistently.
This current paper has shown that the tool largely reproduces GRADE judgements in a vari-
ety of scenarios which is consistent with other pilot evaluations of the tool. We have found evi-
dence of moderate to substantial agreement between researchers’ responses to the checklist
questions of the tool [17]. Similarly we have found moderate to substantial agreement on
judgements for GRADE domains and overall quality ratings made by independent users of the
tool [31] although further work is needed to improve agreement [31].
A less critical, but interesting property of the probabilistic assessment is the ability to accrue
small probabilities across domains, resulting in accurate downgrading where multiple small
but nonetheless important uncertainties exist. GRADE does allow uncertainties across multiple
domains to be summed with a choice regarding the domain responsible for downgrading [2–
16] but this is a pragmatic solution that can be hard to apply, particularly in a situation where
there is a small probability of bias (say 0.2) in every domain. Rationally this should result in a
downgrade from high to moderate quality evidence, but in practice users may operate using
higher thresholds to signal concerns. For example, in our pilot evaluation comparing with stan-
dard GRADE assessments by an expert user we found a number of occasions where our tool
was more conservative in judgements due to accumulation of probabilities across domains not
taken into account in standard assessments [31].
In addition to providing a potential tool for the semi-automation of GRADE assessments,
the Bayesian network may prove useful as a focus for methodological development. Some as-
pects of the GRADE framework are better supported by evidence than others. Changing the
structure and parameterisation of the model allows exploration of the relative importance of
different components. Methodological applications could involve mapping empirical probabil-
ities and applying them or formally eliciting expert opinion to generate distributions for the
probabilities, appropriately reflecting uncertainty. Other theoretical work could focus on the
value of information associated with different problems, or relating quality of evidence to other
aspects of research synthesis conduct via meta-epidemiology.
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The impact of changes to the GRADE framework can be quantified and explored. For exam-
ple, what is the impact of severe downgrading for moderate problems only when they are iden-
tified across five domains, rather than two? Probabilistic assessment could also facilitate
comparison with other tools or allow adaptation for specific settings or other contexts such as
syntheses of narrative, qualitative and non-randomised studies.
Probabilistic assessment has two other potentially desirable features. First, the reliability as-
sessment can be represented as a probability distribution, allowing uncertainty to be expressed
where appropriate. The approach also lends itself to automation, where nodes can be parame-
terised either using data mining software [32] or where frameworks such as ARCHIE (the
Cochrane Collaboration's central server for managing documents) underpin review production
and structure. Automation of research synthesis activities are receiving increasing attention
[33], driven by increasing quantities of information and the need to inform ever more complex
decisions with evidence efficiently. Probabilistic approaches may provide a future mechanism
for automation of reliability assessment, which has hitherto been a missing component in pro-
posed mechanisms for automated research synthesis.
Potential limitations of the tool
A key strength of GRADE is that it forces users to make judgements about both the sources of
bias and overall quality. The judgements may or may not be appropriate, but they are transpar-
ent. The Bayesian network uses the same logic in determining node states, for example forcing
judgement that blinding of participants leads to bias or it does not. The subsequent impact of
this decision is however, not left to the reviewers judgement. This is both strength and a weak-
ness. The strength is that the impact of bias is consistent. The weakness is that the impact of
blinding on risk of bias is dependent upon further context, which is unknown. In most circum-
stances, problems with blinding alone should not result in downgrading (which is how the
Bayesian network is parameterised), but there are circumstances when the resulting perfor-
mance bias may have serious or even very serious implications, downgrading high quality evi-
dence. In theory, the factors which relate to the impact of blinding can be added to the
Bayesian network, but in practice, beyond considering generic issues such as whether the out-
come is objective, the network becomes overly complex for straightforward application. Fur-
ther development of the evidence base underpinning the impact of biases may be required to
address this issue adequately. Similar issues are raised when considering the impact of indirect
comparisons given the diversity of views and embryonic evidence base regarding the relative
merits of direct and indirect evidence in different contexts.
An uncertainty about our tool at present is the extent to which probabilities in our Bayesian
network transfer across diverse topic areas. One of the advantages of our tool is that is that it
provides a sound theoretical framework (through the use of Bayesian networks) to investigate
these issues empirically in the future and as the evidence accumulates modifications to the
model can be applied. Alternatively, there is sufficient flexibility in our approach that reviewers
with belief or evidence that bias operates uniquely for a particular topic, outcome, or treatment
comparison may modify the probabilities according to background knowledge as all inputs to
the model have been made publically available in supplementary materials.
An advantage of our model is that it estimates the uncertainty in judgements on the strength
of a body of evidence (e.g. 90% probability the evidence is low quality and 10% probability that it
is moderate quality). In the present paper we haven’t determined specific thresholds for inter-
preting this uncertainty (e.g. if there is 90% probability of low quality evidence is that sufficient
to conclude the body of evidence is low?). This is to allow flexibility for users and decision-mak-
ers to apply the tool in a way that reflects their needs and their context regarding interpretation
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of uncertainty. However, further work engaging with users and decision-makers applying the
tool may be needed to identify whether determining more specific thresholds for interpretation
would be beneficial. Thus, a collaborative GRADE assessment undertaken by experienced meth-
odologists in conjunction with relevant subject experts is likely to yield a more nuanced validity
assessment provided that the complexity of the decisions do not result in incoherence. It is also
true that parameterisation of the Bayesian network requires a degree of training as it involves
subjective value judgements notably regarding minimal important difference. Whilst it is possi-
ble to conceptualise a probabilistic model informed by systematically collated evidence or belief
regarding these uncertainties, such a framework remains a distant reality. Ultimately the
strengths and limitations of the Bayesian network and a standard approach to GRADE depend
on the extent to which expert judgements are required to inform a validity assessment.
Conclusions
Bayesian networks have considerable potential to facilitate probabilistic assessment of the reli-
ability of research evidence. The key strength of such networks lies in the provision of a statisti-
cally coherent method for combining probabilities across a complex framework based on both
belief and evidence. In addition to providing tools for less experienced users to implement reli-
ability assessment, the potential for sensitivity analyses may be beneficial for the methodologi-
cal development of reliability tools, and automation may also lead to efficiency gains.
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